{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:20:56Z","timestamp":1791170456637,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Doxycycline is widely used to treat various bacterial infections and has significant global implications, especially as the preferred medication for scrub typhus and leptospirosis. However, its use is limited in children below 8\u00a0years of age due to potential adverse effects on teeth and bones. This study aims to assess the risk of dental adverse events associated with doxycycline, a tetracycline-class antibiotic, in children under 8\u00a0years of age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this review, we searched PubMed, the Cochrane Library, and Google Scholar for studies published until November 2023. We included studies administering doxycycline to children under 8\u00a0years, focusing on dose, duration, and dental adverse events to assess the safety of doxycycline.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>A total of 325 articles were initially retrieved, of which 5 studies were available for analysis. This review included information on 162 children who were treated with doxycycline between the ages of 0 and 8\u00a0years. The median age at doxycycline administration was 4.25\u00a0years and interquartile range (IQR) of 2.065\u20135.563\u00a0years. The oral dosage, based on weight, had a median of 2.3\u00a0mg\/kg\/day, with an IQR of 1.525\u20135.438\u00a0mg\/kg\/day. The median duration of drug administration was 8.5 days and the IQR of 6\u201312.5\u00a0days. We found a pooled proportion of adverse events of 0.21 (95% CI: 0.13\u20130.28).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This review suggests that the occurrence of teeth-related adverse events with short-term doxycycline use is minimal, with a low incidence reported. While these findings offer a preliminary basis for the use of doxycycline in children under 8\u00a0years of age, the limited number of studies underscore the need for further research to evaluate its therapeutic use and implication for paediatric guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/myprospero<\/jats:ext-link>, Identifier CRD42023494713.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1646638","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:42:43Z","timestamp":1758692563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Dental safety of short-term doxycycline use in children under 8 years: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Anusiga Sigamani","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumidha","family":"Periyathambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijesh Sreedhar","family":"Kuttiatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/archdischild-2016-310964","article-title":"QUESTION 1: teething issues: can doxycycline be safely used in young children?","volume":"101","author":"Boast","year":"2016","journal-title":"Arch. Dis. Child."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"B3","volume-title":"Clinical Care of Rocky Mountain Spotted Fever","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1517\/14740338.2016.1133584","article-title":"Revisiting doxycycline in pregnancy and early childhood\u2013time to rebuild its reputation?","volume":"15","author":"Cross","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B15","unstructured":"RoB 2: A revised Cochrane risk-of-bias tool for randomized trials\n          \n          \n          2025"},{"key":"B6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.4269\/ajtmh.2012.11-0453","article-title":"Fatal rocky Mountain spotted fever in the United States, 1999-2007","volume":"86","author":"Dahlgren","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/s0140-6736(69)91787-5","article-title":"Doxycycline and the teeth","volume":"1","author":"Forti","year":"1969","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1542\/peds.47.3.567","article-title":"Tetracyclines and permanent teeth: the relation between dose and tooth color","volume":"47","author":"Grossman","year":"1971","journal-title":"Pediatrics"},{"key":"B4","unstructured":"Critical Appraisal Tools\n          \n          \n          2025"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1542\/9781610025225","volume-title":"Red book: 2021\u20132024 report of the committee on infectious diseases","author":"Kimberlin","year":"2021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/00006454-199805000-00019","article-title":"Doxycycline and staining of permanent teeth","volume":"17","author":"Lochary","year":"1998","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3201\/eid2308.170025","article-title":"Scrub typhus as a cause of acute encephalitis syndrome, gorakhpur, Uttar Pradesh, India","volume":"23","author":"Mittal","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"B12","first-page":"HS2","article-title":"Doxycycline-associated tooth staining in young children","volume":"44","author":"Nieves","year":"2019","journal-title":"Pharmacist"},{"key":"B13","first-page":"668","article-title":"Controlled study of the effect of prenatal tetracycline on primary dentition","volume":"5","author":"Porter","year":"1965","journal-title":"Antimicrob. Agents Chemother. (Bethesda)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1093\/jac\/dkx245","article-title":"Dental staining after doxycycline use in children","volume":"72","author":"P\u00f6yh\u00f6nen","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1128\/AAC.00262-07","article-title":"Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"51","author":"Ruhe","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B17","first-page":"692","article-title":"The effect of long-term antibiotic therapy in patients with cystic fibrosis of the pancreas","volume":"6","author":"Shwachman","year":"1958","journal-title":"Antibiot. Annu."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1177\/1060028019863796","article-title":"Doxycycline and tooth discoloration in children: changing of recommendations based on evidence of safety","volume":"53","author":"Stultz","year":"2019","journal-title":"Ann. Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13312-020-1889-4","article-title":"Effectiveness of presumptive treatment of acute febrile illness with doxycycline or azithromycin in preventing acute encephalitis syndrome in gorakhpur, India: a cohort study","volume":"57","author":"Thangaraj","year":"2020","journal-title":"Indian Pediatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.jpeds.2015.02.015","article-title":"No visible dental staining in children treated with doxycycline for suspected rocky Mountain spotted fever","volume":"166","author":"Todd","year":"2015","journal-title":"J. Pediatr."},{"key":"B21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/0009922806290026","article-title":"Absence of tooth staining with doxycycline treatment in young children","volume":"46","author":"Volovitz","year":"2007","journal-title":"Clin. Pediatr. (Phila)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/s0140-6736(62)91840-8","article-title":"Teeth pigmented by tetracycline","volume":"1","author":"Wallman","year":"1962","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1097\/INF.0000000000002453","article-title":"Is doxycycline appropriate for routine treatment of young children with erythema Migrans?","volume":"38","author":"Wormser","year":"","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.diagmicrobio.2018.09.015","article-title":"How safe is doxycycline for young children or for pregnant or breastfeeding women?","volume":"93","author":"Wormser","year":"","journal-title":"Diagn Microbiol. Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jpeds.2013.10.008","article-title":"Self-reported treatment practices by healthcare providers could lead to death from rocky Mountain spotted fever","volume":"164","author":"Zientek","year":"2014","journal-title":"J. Pediatr."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:42:45Z","timestamp":1758692565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":25,"alternative-id":["10.3389\/fphar.2025.1646638"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1646638","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"article-number":"1646638"}}